A 10-fold increase in rocket launches would start harming the ozone layer

By Laura Revell, Michele Bannister of
SpaceX Starship, shown sitting to the right of the launch tower beside the Super Heavy booster, is set to lift off on Monday for an integrated test flight of the rocket system.
Photo:via CNN Newsource
The international space industry is on a growth trajectory, but new research shows a rapid increase in rocket launches would damage the ozone layer.
Several hundred rockets are launched globally each year by a mix of commercial companies and nation-state space programmes. These take place at around 20 sites, almost all in the Northern Hemisphere, with the most prolific
launch rates
currently from the United States, China, New Zealand and Russia.
Our
latest research
explores the tipping point when launching more rockets will begin to cause problems. Our findings show that once rates reach 2,000 launches a year - about a ten-fold increase on last year - the current healing of the ozone layer slows down.
We argue that with care, we can avoid this future. The economic benefits of industry growth can be realised, but it will take a collaborative effort.
The
ozone layer
protects life on Earth from harmful solar ultraviolet (UV) rays. It is slowly
healing
from the effects of chlorofluorocarbons and other damaging chemicals emitted last century, thanks to
global cooperative agreements
under the
Montreal Protocol
.
Gases and particulates emitted by rockets as they punch through the atmosphere are known to
thin the ozone layer
. So far, they don't cause appreciable ozone depletion, as relatively few launches take place each year.
However, launches are steadily increasing. In 2019, there were 102 launches. By 2024, that increased to 258 worldwide. There are expected to be even more in 2025. At multiple sites worldwide, the launch industry projects impressive levels of future growth.
For US-based launches, a three-fold increase in the number of rockets launched in 2023 is expected
as soon as 2028
.
One driver of this growth is the effort to build out
satellite constellations
to tens of thousands of units, positioned low in Earth's orbit. These require many launches to create and are
happening
in several nations, run by a number of companies.
Once in place, these constellations require ongoing launches to keep them supplied with active satellites.
To figure out how future launches could affect the ozone layer, we first built a
database of ozone-depleting chemicals emitted by rockets
currently in use. We then fed this database into a model of Earth's atmosphere and climate, and simulated atmospheric composition under several scenarios of higher rates of rocket launches.
We found that with around 2000 launches worldwide each year, the ozone layer thins by up to 3 percent. Due to atmospheric transport of rocket-emitted chemicals, we saw the largest ozone losses over Antarctica, even though most launches are taking place in the Northern Hemisphere.
Fortunately, the ozone losses are small. We wouldn't expect to see catastrophic damage to humans or ecosystems. However, the losses are significant given global efforts underway to heal the ozone layer. The global abundance of ozone is still around 2 percent lower than before the onset of losses caused by chlorofluorocarbons.
Photo:
Twitter/SpaceX
Encouragingly, we found no significant ozone loss in a scenario of more modest rates of around 900 launches per year. However, this is for the types of rockets that are in use right now around the world.
We focus on current launch vehicles because it is uncertain when the new and massive rockets currently in development will enter use. But these larger rockets often require far more fuel, which creates more emissions at each launch.
Rocket propellant choices make a big difference to the atmosphere. We found fuels emitting chlorine-containing chemicals or black carbon particulates have the largest effects on the ozone layer. Reducing use of these fuels as launch rates increase is key to supporting an ongoing recovery of the ozone layer.
Re-entering spacecraft and satellite debris can also cause damage. However, the global scientific community doesn't yet fully understand the chemistry around re-entry. Our work provides a realistic "floor" for the lowest level of damage that will occur.
But it is important to remember that these effects are not locked in. It is entirely possible to create a launch industry where we avoid harmful effects, but that would require reducing use of chlorine-containing fuels, minimising black carbon emissions by new rockets and monitoring emissions.
It will take keen effort and enthusiasm from industry and regulators, working together with scientists. But this needs to start now, not after the damage is done.
-
This story
originally appeared on The Conversation.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

RNZ News

6 hours ago

• RNZ News

New mapping technology to help Auckland Council combat major flooding events

Lidar imagery showing detailed river bed and bush. Photo: Supplied / Auckland Council Cutting edge mapping technology is helping Auckland Council combat major flooding events, like the 2023 Anniversary Weekend floods . A low flying EC120 helicopter equipped with Light Detection and Ranging sensors (Lidar) has been mapping the city's critical waterways, creating virtual walkthroughs of stream networks that will help detect environmental changes and identify where infrastructure upgrades are needed. It's part of the council's Making Space for Water (MSFW) programme, aimed at enhancing flood resistance across Auckland. Auckland Council's healthy waters manager Craig Mcilroy said the technology was like progressing from X-ray to MRI for the environment, capturing the health of a catchment's stormwater network. "By using Lidar technology, we're obtaining a level of detail we've never had before," he said. "This data will help us visualise and understand the intricacies of Auckland's waterways in a way that hasn't been possible, right down to individual trees, slips, and bank conditions. It will equip us to tackle the challenges of urban flooding and climate change head-on." "It's a game-changer for managing flood risks and ensuring the city's resilience for future generations," Mcilroy said. So far about 560 square kilometres of the city's north and west has been mapped with high-resolution data, covering areas from Matakana and Whangateau in the north, to the urban catchments of Meola, Swanson and Henderson Creeks, Whenuapai and the North Shore. With laser-point densities reaching 250 points per square metre, the resulting datasets are over 20 times more detailed than Auckland's current regional Lidar data. The stormwater network data collection is being led by Auckland Council principal of waterways planning Danny Klimetz with support from Professor James Brasington, director of the Waterways Centre for Freshwater Management at Canterbury University, with Christchurch Helicopters providing air support. "These datasets are essential for building accurate flood models, tracking erosion, and planning for the future of Auckland's waterways," Professor Brasington said. Lidar imagery showing precision of the technology. Photo: Supplied / Auckland Council Danny Klimetz is the original concept designer and brings a wealth of experience to the project. He said the undertaking highlighted the value of collaborative innovation. "Drawing from my work in the United States, it's satisfying to see we've been able to adapt this method and apply it here to New Zealand's unique landscape," Klimetz said. "With Lidar, we're creating a detailed digital elevation model that not only defines catchment shapes but also identifies vegetation, erosion, and blockages. This clarity is critical for informed decision-making and long-term planning." "By collaborating with experts like those at the University of Canterbury, we're setting a new benchmark for how councils can manage water systems effectively," he said. Lidar technology has a wide variety of applications, including Agriculture, Archaeology, Spaceflight and Law enforcement with Auckland Mayor Wayne Brown saying he's been using Lidar in his own companies for years. He said the council would be implementing many more innovation and technology initiatives in the coming years. "I'm also keen to get on with rolling out AI in the council so we can keep up with business around us," he said. "Growth in the technology sector is a core focus of work in my refreshed manifesto. This is also part of our plan to modernise services. We must make better use of technology to make the council faster and more efficient. "The Making Space for Water programme will be more effective and developed faster because of this; it's another move that will help build physical and financial resilience into Auckland for future generations," Brown said. Sign up for Ngā Pitopito Kōrero , a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

RNZ News

a day ago

• RNZ News

Genetic marker found for rare children's brain disease

A New Zealand-led research team has found new information about the cause of microcephaly, a disease that affects brain growth and function in children. Photo: Image by Gerd Altmann from Pixabay An Otago-led team has uncovered a genetic cause for a rare children's brain disorder. University of Otago associate professor Louise Bicknell, co-author of the study, said the international research team were investigating microcephaly, a developmental disorder where children's brains fail to grow. Dr Louise Bicknell says new research has helped pinpoint a genetic cause of the devastating children's brain disease microcephaly. Photo: Supplied/ University of Otago - Sharron Bennett They pinpointed specific changes in a gene called CRNKL1, and their findings were recently published in the prestigious American Journal of Human Genetics. It was the culmination of a seven-year study of a New Zealand family, Bicknell said. "Their wee girl had really severe microcephaly. Her brain was much smaller than we'd hoped for, and there were quite a few structural things that were abnormal about her brain, so quite unusual." Researchers compared her brain structure with that of nine children overseas who also had the condition. "It was only then that, we realised they all had similar features, of a really small brain, as well as these structural [aspects] of other parts of the brain not being so usual." In a striking discovery, nine of the families also showed genetic changes in the exact same spot in the CRNKL1 gene. It proved there was a strong link between these specific genetic changes and the disorder, and it was an exciting breakthrough, she said. "That's when the heart starts racing and you know you are onto something. Your gut instinct kicks in and says, this can't be a coincidence, this must be something." Lead author Dr Sankalita Ray Das, a postdoctoral fellow at Otago's Rare Disorder Genetics Laboratory, said the research findings clearly showed that CRNKL1 was "crucial" for healthy brain development. "Importantly, this knowledge has provided understanding for families affected by these severe conditions and lays the foundation for further research into why just the brain is affected by these genetic changes." The researchers received funding from the Neurological Foundation of New Zealand, Cure Kids and the University of Otago, Bicknell said. Sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.

RNZ News

2 days ago

• RNZ News

Experimental new drug results in up to 24pct weight loss, comes in a pill

By Deena Beasley , Reuters The full trial results were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal. Photo: 123rf Novo Nordisk on Friday (local time) said full results from early-stage trials show that its experimental drug, amycretin, helped overweight and obese adults lose up to 24 percent of their weight as the Danish company readies for late-stage studies to start next year. The company said side effects of the drug, tested as both a weekly injection and a daily pill, were mostly gastrointestinal with rates similar to other recent weight loss drugs. The [ full trial results[ were presented at the annual meeting of the American Diabetes Association in Chicago and published in the Lancet medical journal. Novo's head of development Martin Holst Lange said the Phase 3 amycretin program starting in 2026 will run "for a couple of years" after which the regulatory review process could start. The company earlier this month said it planned to start late-stage trials of the drug in the first quarter of 2026 after previously announcing the early-stage trial results. Amycretin has a dual-mode action. Like Novo's popular weight-loss drug Wegovy, it mimics the gut hormone GLP-1, but also targets receptors for a hunger-suppressing pancreatic hormone called amylin. Trial results showed that 20-milligram weekly injections of the drug helped overweight or obese patients without diabetes lose 22 percent of their weight over 36 weeks, with a 60-mg dose resulting in 24.3 percent weight loss. In the Phase 1 study of once-daily oral amycretin, patients received increasing doses, ranging from 3 mg to a final dose of 100 mg. Patients who took 50 mg of amycretin at the end of the 12-week trial reduced body weight by 10.4 percent on average, while those taking the maximum dose lost 13.1 percent of their weight, the company said. Novo said the weight loss did not plateau, suggesting that longer treatment could lead to greater weight loss. In a Lancet commentary, researchers not involved in the amycretin studies said that "while additional weight loss is welcome and helpful, our evolving concept of obesity management has now shifted towards an emphasis on the reduction of the risks and burdens of cardiovascular disease and other comorbidities". Commentators Tricia Tan, professor of metabolic medicine and endocrinology at Imperial College London, and endocrinologist Dr Bernard Khoo, said studies directly comparing GLP-1 drugs like Novo's Ozempic to drugs like amycretin will be needed to definitively establish their added value and place in obesity management. - Reuters